Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Milestone Scientific (MLSS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Milestone Scientific (MLSS) over the last 16 years, with Q3 2025 value amounting to $1.3 million.

  • Milestone Scientific's Cash & Equivalents fell 7182.97% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 7182.97%. This contributed to the annual value of $3.3 million for FY2024, which is 1082.33% up from last year.
  • Latest data reveals that Milestone Scientific reported Cash & Equivalents of $1.3 million as of Q3 2025, which was down 7182.97% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Milestone Scientific's Cash & Equivalents peaked at $17.0 million during Q1 2021, and registered a low of $1.3 million during Q2 2025.
  • In the last 5 years, Milestone Scientific's Cash & Equivalents had a median value of $4.8 million in 2024 and averaged $7.3 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 211295.86% in 2021, then plummeted by 8281.41% in 2023.
  • Over the past 5 years, Milestone Scientific's Cash & Equivalents (Quarter) stood at $14.8 million in 2021, then tumbled by 40.97% to $8.7 million in 2022, then plummeted by 65.83% to $3.0 million in 2023, then rose by 10.82% to $3.3 million in 2024, then plummeted by 59.23% to $1.3 million in 2025.
  • Its Cash & Equivalents was $1.3 million in Q3 2025, compared to $1.3 million in Q2 2025 and $2.2 million in Q1 2025.